Technical Report abstract
Nature Medicine 14, 343 - 349 (2008)
Published online: 24 February 2008 | doi:10.1038/nm1691
Noninvasive assessment of cancer response to therapy
Zhaozhong Han1, Allie Fu1, Hailun Wang1,2, Roberto Diaz1, Ling Geng1, Halina Onishko1 & Dennis E Hallahan1,2,3,4
Rapid assessment of cancer response to a therapeutic regimen can determine efficacy early in the course of treatment. Although biopsies of cancer can be used to rapidly assess pharmacodynamic response, certain disease sites are less accessible to repeated biopsies. Here, we simultaneously assess response in all sites of disease within days of starting therapy by use of peptide ligands selected for their ability to discern responding from nonresponding cancers. When conjugated to near-infrared imaging agents, the HVGGSSV peptide differentiates between these two types of cancer. Rapid, noninvasive assessment of the pharmacodynamic response within cancer promises to accelerate drug development and minimize the duration of treatment with ineffective regimens in cancer patients.
- Department of Radiation Oncology, School of Medicine, Vanderbilt University, 1301 22nd Avenue South, B902 TVC, Nashville, Tennessee 37232, USA.
- Department of Cancer Biology, School of Medicine, Vanderbilt University, 1301 22nd Avenue South, B902 TVC, Nashville, Tennessee 37232, USA.
- Department of Biomedical Engineering, School of Medicine, Vanderbilt University, 1301 22nd Avenue South, B902 TVC, Nashville, Tennessee 37232, USA.
- Vanderbilt-Ingram Cancer Center, 1301 22nd Avenue South, B902 TVC, Nashville, Tennessee 37232, USA.
Correspondence to: Dennis E Hallahan1,2,3,4 e-mail: dennis.hallahan@vanderbilt.edu
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Identification of IGFBP-6 as an effector of the tumor suppressor activity of SEMA3BOncogene Original Article
